At a glance
- Originator Merck & Co
- Class Anti-ischaemics; Antiplatelets; Vascular disorder therapies
- Mechanism of Action Fibrinogen receptor antagonists; GPIIb-IIIa antagonists; Platelet aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis